Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain TreatmentGlobeNewsWire • 11/13/24
Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine ProgramGlobeNewsWire • 07/24/24
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human InsulinGlobeNewsWire • 06/24/24
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded AccessBusiness Wire • 03/07/24
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation TherapyBusiness Wire • 03/06/24
Creative Medical Technology Granted FDA Clearance for Chronic Back Pain Clinical TrialMCAP MediaWire • 12/21/23
Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back PainAccesswire • 12/20/23
Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back PainPRNewsWire • 10/10/23
What Makes Creative Medical Technology Holdings, Inc. (CELZ) a New Buy StockZacks Investment Research • 09/22/23
Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back PainPRNewsWire • 09/19/23
What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?Accesswire • 08/24/23
The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this GrowthAccesswire • 07/14/23
Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate UpdateAccesswire • 07/13/23
Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing RequirementsPRNewsWire • 06/28/23
Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy PlatformPRNewsWire • 05/31/23
Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform DevelopmentPRNewsWire • 05/22/23
Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell LinePRNewsWire • 05/18/23
Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes StudyPRNewsWire • 04/12/23